Related Experiment Video
Updated: Oct 26, 2025

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
Published on: May 7, 2020
Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
Evan C Klein1, Jack Rubinstein2, Jennifer L Strande1,3
1Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract:
A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (Level of Difficulty: Intermediate.).
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management

